{"nctId":"NCT00752973","briefTitle":"Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice","startDateStruct":{"date":"2008-09"},"conditions":["Pediculosis"],"count":12,"armGroups":[{"label":"Treatment arm","type":"EXPERIMENTAL","interventionNames":["Drug: MALG (malathion) Treatment"]}],"interventions":[{"name":"MALG (malathion) Treatment","otherNames":["Novel malathion formulation"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed active head lice infestation\n\nExclusion Criteria:\n\n* Allergy to pediculicides or hair care products\n* Scalp conditions other than head lice\n* Previous head lice treatment within the past 4 weeks\n* Current antibiotic treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Months","maximumAge":"24 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants With a Change in Cholinesterase Level at 1 Hour (Day 0).","description":"Each patient (aged 6 - 24 months) was assessed at 1 hour (Day 0). The mean percent change (reduction) in plasma and RBC cholinesterase activity from baseline to 1 hr after application was calculated and accompanied by 95% confidence intervals.\n\nIf the half-widths of the derived confidence intervals are sufficiently narrow, it will demonstrate that any observed reductions in plasma and RBC cholinesterase activity fall within established safety guidelines.\n\nConcentration of RBC-cholinesterase (RBC-ChE) and plasma cholinesterase were obtained at baseline, at 1 hr (Day 0) and at 24 hrs (Day 1) after the application of the treatment.\n\nMean percent change (reduction) = (Post treatment value - Baseline)/ Baseline x100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Participants With a Change in Cholinesterase Level at 24 Hrs (1 Day).","description":"Each patient was assessed at Day 1 and the mean percent reduction in plasma and RBC cholinesterase activity from baseline to 24 hr after application was calculated and accompanied by 95% confidence intervals.\n\nConcentration of RBC-cholinesterase (RBC-ChE) and plasma cholinesterase were obtained at baseline, at 1 hr (Day 0) and at 24 hrs (Day 1) after the application of the treatment.\n\nMean percent reduction = (Post treatment value - Baseline)/ Baseline x100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Participants With the Clinical Evidence of Cholinesterase Inhibition","description":"Participants with any of the following symptoms of cholinesterase inhibition as numbered below were considered to have Clinical evidence of cholinesterase inhibition.\n\n1. Abnormal heart rate.\n2. Diarrhea or abdominal cramps.\n3. Inappropriate sweating.\n4. Pupillary miosis (constriction).\n5. Respiratory difficulty such as chest tightness or wheezing.\n\nOne participant had wheezing as medical history which continued without increase in severity throughout the treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Participants With the Clinical Evidence of Cholinesterase Inhibition","description":"Participants with any of the following symptoms of cholinesterase inhibition as numbered below were considered to have Clinical evidence cholinesterase inhibition :\n\n1. Abnormal heart rate.\n2. Diarrhea or abdominal cramps.\n3. Inappropriate sweating.\n4. Pupillary miosis (constriction).\n5. Respiratory difficulty such as chest tightness or wheezing.\n\nOne participants had wheezing as medical history which continued without increase in severity throughout the treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Participants With the Clinical Evidence of Cholinesterase Inhibition","description":"Participants with any of the following symptoms of cholinesterase inhibition as numbered below were considered to have Clinical evidence of cholinesterase inhibition :\n\n1. Abnormal heart rate.\n2. Diarrhea or abdominal cramps.\n3. Inappropriate sweating.\n4. Pupillary miosis (constriction).\n5. Respiratory difficulty such as chest tightness or wheezing.\n\nOne participants had wheezing as medical history which continued without increase in severity throughout the treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Participants Clinically Cured of Head Lice 14 Days After Last Treatment","description":"No live lice (including adults and nymphs) and nits at Day 7Â±1 and final lice assessment on either Day 14 (subjects not requiring retreatment) or Day 21 (for retreated subjects).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluation of the Local Safety of Malathion Gel, 0.5% Based Upon Reported Adverse Events and Observed Scalp Reactions.","description":"To evaluate the safety of Malathion Gel, 0.5% based upon reported adverse events and observed scalp reactions. Additional safety assessments included eye Irritation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Cough","Diarrhoea","Head injury","Wheezing"]}}}